Patterns of failure for conservatively managed surgical stage I uterine carcinosarcoma: Implications for adjuvant therapy

International Journal of Gynecological Cancer

Volumn 19, Issue 5, 2009, Pages 888-891

  Leath III, Charles A ^a   Numnum, T Michael ^a   Kendrick IV, James E ^a   Frederick, Peter J ^a   Rocconi, Rodney P ^a   Conner, Michael G ^b   Straughn Jr , J Michael ^a  

^a Division of Gynecologic Oncology   (United States)

^b University of Alabama at Birmingham   (United States)

Author keywords

Mixed mesodermal tumor; Outcomes; Surgical staging; Uterine carcinosarcoma

Indexed keywords

ANTINEOPLASTIC AGENT;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ARTICLE; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; DEMOGRAPHY; ENDOMETRIOID CARCINOMA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LYMPHADENECTOMY; OVERALL SURVIVAL; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; RECURRENT CANCER; SALPINGOOOPHORECTOMY; TREATMENT FAILURE; UTERUS CANCER; UTERUS CARCINOSARCOMA; ADJUVANT CHEMOTHERAPY; CARCINOSARCOMA; CYSTADENOCARCINOMA; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOSARCOMA; CHEMOTHERAPY, ADJUVANT; CYSTADENOCARCINOMA, PAPILLARY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; TREATMENT FAILURE; UTERINE NEOPLASMS;

EID: 69449098378     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a831fb     Document Type: Article

References (27)

1. Echt G, Jepson J, Steel J, et al. Treatment of uterine sarcomas. Cancer. 1990;66:35-39.
2. Harlow BL, Weiss NS, Lofton S. The epidemiology of sarcomas of the uterus. J Natl Cancer Inst. 1986;76:399-402.
3. Olah KS, Dunn JA, Gee H. Leiomyosarcomas have a poorer prognosis than mixed mesodermal tumours when adjusting for known prognostic factors: the result of a retrospective study of 423 cases of uterine sarcoma. Br J Obstet Gynaecol. 1992;99:590-594.
4. Sutton G, Kauderer J, Carson LF, et al. Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study. Gynecol Oncol. 2005;96:630-634.
5. Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer. 1993;71:1702-1709.
6. Kilgore LC, Partridge EE, Alvarez RD, et al. Adenocarcinoma of the endometrium: survival comparisons of patients with and without pelvic node sampling. Gynecol Oncol. 1995;56:29-33.
7. Naumann RW, Coleman RL. The use of adjuvant radiation therapy in early endometrial cancer by members of the Society of Gynecologic Oncologists in 2005. Gynecol Oncol. 2007;105:7-12.
8. Creasman WT, Odicino F, Maisonneuve P, et al. Carcinoma of the corpus uteri. Int J Gynaecol Obstet. 2003;83:79-118.
9. Gerszten K, Faul C, Kounelis S, et al. The impact of adjuvant radiotherapy on carcinosarcoma of the uterus. Gynecol Oncol. 1998;68:8-13.
10. Kanjeekal S, Chambers A, Fung MF, et al. Systemic therapy for advanced uterine sarcoma: a systematic review of the literature. Gynecol Oncol. 2005;97:624-637.
11. Chi DS, Mychalczak B, Saigo PE, et al. The role of whole-pelvic irradiation in the treatment of early-stage uterine carcinosarcoma. Gynecol Oncol. 1997;65:493-498.
12. Molpus KL, Redlin-Frazier S, Reed G, et al. Postoperative pelvic irradiation in early stage uterine mixed müllerian tumors. Eur J Gynaecol Oncol. 1998;19:541-546.
13. Wolfson AH, Brady MF, Rocereto T, et al. A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus. Gynecol Oncol. 2007;107:177-185.
14. Reed NS, Mangioni C, Malmstrom H, et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer. 2008;44:808-818.
15. Creasman WT, Morrow CP, Bundy BN, et al. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group study. Cancer. 1987;60:2035-2041.
16. DiSaia PJ, Castro JR, Rutledge FN. Mixed mesodermal sarcoma of the uterus. Am J Roentgenol Radium Ther Nucl Med. 1973;117:632-636.
17. Hornback NB, Omura G, Major FJ. Observations on the use of adjuvant radiation therapy in patients with stage I and II uterine sarcoma. Int J Radiat Oncol Biol Phys. 1986;12:2127-2130.
18. Larson B, Silfversward C, Nilsson B, et al. Mixed müllerian tumours of the uterusVprognostic factors: a clinical and histopathologic study of 147 cases. Radiother Oncol. 1990;17:123-132.
19. Perez CA, Askin F, Baglan RJ, et al. Effects of irradiation on mixed müllerian tumors of the uterus. Cancer. 1979;43:1274-1284.
20. Homesley HD, Filiaci V, Markman M, et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group study. J Clin Oncol. 2007;25:526-531.
21. Keys HM, Roberts JA, Brunetto VL, et al. A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2004;92:744-751.
22. Straughn JM Jr, Huh WK, Kelly FJ, et al. Conservative management of stage I endometrial carcinoma after surgical staging. Gynecol Oncol. 2002;84:194-200.
23. Amant F. The rationale for comprehensive surgical staging in endometrial carcinosarcoma. Gynecol Oncol. 2005;99:521Y522; author reply 2-3.
24. Yamada SD, Burger RA, Brewster WR, et al. Pathologic variables and adjuvant therapy as predictors of recurrence and survival for patients with surgically evaluated carcinosarcoma of the uterus. Cancer. 2000;88:2782-2786.
25. Arrastia CD, Fruchter RG, Clark M, et al. Uterine carcinosarcomas: incidence and trends in management and survival. Gynecol Oncol. 1997;65:158-163.
26. Temkin SM, Hellmann M, Lee YC, et al. Early-stage carcinosarcoma of the uterus: the significance of lymph node count. Int J Gynecol Cancer. 2007;17:215-219.
27. Silverberg SG, Major FJ, Blessing JA, et al. Carcinosarcoma (malignant mixed mesodermal tumor) of the uterus. A Gynecologic Oncology Group pathologic study of 203 cases. Int J Gynecol Pathol. 1990;9:1-19.